Alzheimers
0
Maynard Paton | BIOVENTIX: H1 2025 Revenue Up Just 1% Due To ‘Mature’ Markets Leaves £24 Shares Yielding 6%-Plus And Future Growth Seemingly Dependent On Promising Alzheimer’s R&D And Associated Royalty/Supply Arrangements
0

Apologies! This BVXP H1 2025 review has taken somewhat longer than expected to produce. BVXP’s FY 2025 results are due tomorrow (27 October) and to ...

0
Alzheimer’s Awareness Month: Finding Help with Your Memory Care Medications and Support Services
0

Last Updated on November 17, 2025 November is National Alzheimer’s Disease Awareness Month, a time dedicated to raising awareness about Alzheimer’s ...

0
NeuroEM Therapeutics Closes Initial Rounds in $5 Million Equity Raise to Commercialize Drug-free Alzheimer’s Treatment
0

Jun 132025 NeuroEM Therapeutics Closes Initial Rounds in $5 Million Equity Raise to Commercialize Drug-free Alzheimer’s Treatment NeuroEM ...

0
New Alzheimer’s Blood Test Leads To Early Detection And Treatment
0

Image Source: PixabayA new Alzheimer’s blood test recently approved by the U. S. Food and Drug Administration (FDA) can now detect the disease in people ...

0
Maynard Paton | BIOVENTIX: Record H1 2024 Reveals Profit Up 15% Despite Slowing Troponin Growth As Encouraging Alzheimer’s Work Attracts ‘Significant Attention’ And Research-Test Availability Through Quanterix
0

22 October 2024By Maynard Paton H1 2024 results summary for Bioventix (BVXP): A record H1, showing revenue up 13%, profit up 15% and the ...

0
Mental Health Strategies for Alzheimer’s Caregivers |
0

Caring for a loved one with Alzheimer’s disease is a journey filled with both compassion and love as well as emotional, physical, and psychological ...

0
Alzheimer’s Disease – What are the Early Signs |
0

Spring has sprung, and with spring comes Mother’s and Father’s Day. While enjoying the colorful flowers and warm weather with your elderly parents and ...

0
Maynard Paton | BIOVENTIX: £155k R&D Revenue And Commencement Of ‘Large-Scale Production’ Signal Increasing Alzheimer’s Success After Troponin Error Creates Below-Expectations FY 2024 And Leaves Dividend Yield Exceeding 5%
0

04 March 2025By Maynard Paton FY 2024 results summary for Bioventix (BVXP): A record FY, showing revenue up 6% and profit up 5%, although the 3p ...

Som2ny Network
Logo
Register New Account
Compare items
  • Total (0)
Compare
0
Shopping cart